A round 400 million people worldwide are infected with hepatitis B virus (HBV). Chronic hepatitis B (CHB), which is triggered by HBV infection, results in a huge health burden on the global community, as it is correlated with a significantly increased risk for the development of cirrhosis, liver failure, and hepatocellular carcinoma (HCC) (1). Currently, treatment of CHB consists mainly of pegylated alpha interferon (IFN-␣) and nucleoside or nucleotide analogs (e.g., lamivudine, adefovir, and entecavir). IFN-␣ was the first drug licensed to treat HBV infection. As an important first-line treatment option, pegylated IFN-␣ as monotherapy can effectively treat CHB in 25 to 40% of patients, and greater sustained virological responses (SVRs) and hepatitis B virus e antigen (HBeAg) seroconversion rates in HBeAg-positive patients were observed with addition of nucleoside/nucleotide analogue therapies (2, 3). In fact, treatment with pegylated IFN results in the highest rate of off-treatment sustained responses among currently available drugs (4). Moreover, responses to IFNbased therapy are accompanied by the potential for hepatitis B virus surface antigen (HBsAg) loss or seroconversion, and early serum HBsAg loss was recently reported to have predictive value for SVRs to IFN in both HBeAg-positive and -negative CHB patients (5-7).As a member of the type I interferons, IFN-␣ can initiate the activation of Jak/STAT and NF-B signaling, which induces hundreds of IFN-stimulated genes (ISGs) and may play an important role in IFN-mediated anti-HBV activity. Both in vitro and in vivo studies have shown that besides a stimulating effect on cytotoxic T lymphocytes and natural killer cell function, IFN-based therapy (IFN-␣-2b and pegylated IFN-␣-2a or -2b) also has a direct antiviral effect by preventing the formation or accelerating decay of viral capsids and/or inducing antiviral ISGs that inhibit HBV expression and replication (8-13). Inhibition of IFN-␣ signaling by HBV has been suggested to antagonize the IFN response (14).Nevertheless, these studies also strongly suggest that there is significant potential, in principle, to modulate the effectiveness of IFN-mediated anti-HBV activities. Moreover, the antiviral activity of ISGs remains elusive and still awaits further investigation (15). Responses to IFN-␣ therapy vary greatly in CHB patients, but the underlying mechanisms are almost unknown (4-6). Notably, IFN-␣/ was recently found to suppress HBV replication in HBV transgenic mice when the viral load was high, whereas it enhanced HBV replication when the viral load was low, indicating its dual function for HBV (16). Taken together, the data show that the precise mechanism of action of IFN-␣ has not been understood fully.MicroRNAs (miRNAs) are a class of small RNAs of approximately 22 nucleotides (nt) which interact with complementary target sites, usually in the 3=-untranslated region (3=-UTR) of target mRNAs, and induce their translational repression, deadenylation, and degradation. MicroRNA-122 (miR-122), a mammalian liv...